#BEGIN_DRUGCARD DB08271

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C13H20N2O5S

# Chemical_IUPAC_Name:
N-hydroxy-2-[N-(2-methylpropyl)(4-methoxybenzene)sulfonamido]acetamide

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:30:24 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID

# HET_ID:
NGH

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C13H20N2O5S/c1-10(2)8-15(9-13(16)14-17)21(18,19)12-6-4-11(20-3)5-7-12/h4-7,10,17H,8-9H2,1-3H3,(H,14,16)

# InChI_Key:
InChIKey=JIRXORZYIXSWOB-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
8277

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
316.373

# Molecular_Weight_Mono:
316.10929245

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.76

# Predicted_LogS:
-2.7

# Predicted_Water_Solubility:
5.69e-01 g/l

# Primary_Accession_No:
DB08271

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
448002

# PubChem_Substance_ID:
99444742

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC=C(C=C1)S(=O)(=O)N(CC(C)C)CC(=O)NO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:26:39 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted, extracellular space, extracellular matrix (Probable)

# Drug_Target_1_Chromosome_Location:
1

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X07820

# Drug_Target_1_GenBank_ID_Protein:
36629

# Drug_Target_1_GeneCard_ID:
MMP10

# Drug_Target_1_Gene_Name:
MMP10

# Drug_Target_1_Gene_Sequence:
>1431 bp
ATGATGCATCTTGCATTCCTTGTGCTGTTGTGTCTGCCAGTCTGCTCTGCCTATCCTCTG
AGTGGGGCAGCAAAAGAGGAGGACTCCAACAAGGATCTTGCCCAGCAATACCTAGAAAAG
TACTACAACCTCGAAAAGGATGTGAAACAGTTTAGAAGAAAGGACAGTAATCTCATTGTT
AAAAAAATCCAAGGAATGCAGAAGTTCCTTGGGTTGGAGGTGACAGGGAAGCTAGACACT
GACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGACGTTGGTCACTTCAGC
TCCTTTCCTGGCATGCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTAT
ACACCAGATTTGCCAAGAGATGCTGTTGATTCTGCCATTGAGAAAGCTCTGAAAGTCTGG
GAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATGATC
TCTTTCGCAGTTAAAGAACATGGAGACTTTTACTCTTTTGATGGCCCAGGACACAGTTTG
GCTCATGCCTACCCACCTGGACCTGGGCTTTATGGAGATATTCACTTTGATGATGATGAA
AAATGGACAGAAGATGCATCAGGCACCAATTTATTCCTCGTTGCTGCTCATGAACTTGGC
CACTCCCTGGGGCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTACAAC
TCATTCACAGAGCTCGCCCAGTTCCGCCTTTCGCAAGATGATGTGAATGGCATTCAGTCT
CTCTACGGACCTCCCCCTGCCTCTACTGAGGAACCCCTGGTGCCCACAAAATCTGTTCCT
TCGGGATCTGAGATGCCAGCCAAGTGTGATCCTGCTTTGTCCTTCGATGCCATCAGCACT
CTGAGGGGAGAATATCTGTTCTTTAAAGACAGATATTTTTGGCGAAGATCCCACTGGAAC
CCTGAACCTGAATTTCATTTGATTTCTGCATTTTGGCCCTCTCTTCCATCATATTTGGAT
GCTGCATATGAAGTTAACAGCAGGGACACCGTTTTTATTTTTAAAGGAAATGAGTTCTGG
GCCATCAGAGGAAATGAGGTACAAGCAGGTTATCCAAGAGGCATCCATACCCTGGGTTTT
CCTCCAACCATAAGGAAAATTGATGCAGCTGTTTCTGACAAGGAAAAGAAGAAAACATAC
TTCTTTGCAGCGGACAAATACTGGAGATTTGATGAAAATAGCCAGTCCATGGAGCAAGGC
TTCCCTAGACTAATAGCTGATGACTTTCCAGGAGTTGAGCCTAAGGTTGATGCTGTATTA
CAGGCATTTGGATTTTTCTACTTCTTCAGTGGATCATCACAGTTTGAGTTTGACCCCAAT
GCCAGGATGGTGACACACATATTAAAGAGTAACAGCTGGTTACATTGCTAG

# Drug_Target_1_General_Function:
Involved in calcium ion binding

# Drug_Target_1_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16959974	Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.
2844164	Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R: The collagenase gene family in humans consists of at least four members. Biochem J. 1988 Jul 1;253(1):187-92.

# Drug_Target_1_HGNC_ID:
GNC:7156

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6188

# Drug_Target_1_Locus:
11q22.3

# Drug_Target_1_Molecular_Weight:
54150.7

# Drug_Target_1_Name:
Stromelysin-2

# Drug_Target_1_Number_of_Residues:
476

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_1_Protein_Sequence:
>Stromelysin-2
MMHLAFLVLLCLPVCSAYPLSGAAKEEDSNKDLAQQYLEKYYNLEKDVKQFRRKDSNLIV
KKIQGMQKFLGLEVTGKLDTDTLEVMRKPRCGVPDVGHFSSFPGMPKWRKTHLTYRIVNY
TPDLPRDAVDSAIEKALKVWEEVTPLTFSRLYEGEADIMISFAVKEHGDFYSFDGPGHSL
AHAYPPGPGLYGDIHFDDDEKWTEDASGTNLFLVAAHELGHSLGLFHSANTEALMYPLYN
SFTELAQFRLSQDDVNGIQSLYGPPPASTEEPLVPTKSVPSGSEMPAKCDPALSFDAIST
LRGEYLFFKDRYFWRRSHWNPEPEFHLISAFWPSLPSYLDAAYEVNSRDTVFIFKGNEFW
AIRGNEVQAGYPRGIHTLGFPPTIRKIDAAVSDKEKKKTYFFAADKYWRFDENSQSMEQG
FPRLIADDFPGVEPKVDAVLQAFGFFYFFSGSSQFEFDPNARMVTHILKSNSWLHC

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-17

# Drug_Target_1_Specific_Function:
Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. Activates procollagenase

# Drug_Target_1_SwissProt_ID:
P09238

# Drug_Target_1_SwissProt_Name:
MMP10_HUMAN

# Drug_Target_1_Synonyms:
MMP-10
Matrix metalloproteinase-10
SL-2
Transin-2

# Drug_Target_1_Theoretical_pI:
5.59

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MMP12

# Drug_Target_2_GenBank_ID_Gene:
L23808

# Drug_Target_2_GenBank_ID_Protein:
435970

# Drug_Target_2_GeneCard_ID:
MMP12

# Drug_Target_2_Gene_Name:
MMP12

# Drug_Target_2_Gene_Sequence:
>1413 bp
ATGAAGTTTCTTCTAATACTGCTCCTGCAGGCCACTGCTTCTGGAGCTCTTCCCCTGAAC
AGCTCTACAAGCCTGGAAAAAAATAATGTGCTATTTGGTGAGAGATACTTAGAAAAATTT
TATGGCCTTGAGATAAACAAACTTCCAGTGACAAAAATGAAATATAGTGGAAACTTAATG
AAGGAAAAAATCCAAGAAATGCAGCACTTCTTGGGTCTGAAAGTGACCGGGCAACTGGAC
ACATCTACCCTGGAGATGATGCACGCACCTCGATGTGGAGTCCCCGATCTCCATCATTTC
AGGGAAATGCCAGGGGGGCCCGTATGGAGGAAACATTATATCACCTACAGAATCAATAAT
TACACACCTGACATGAACCGTGAGGATGTTGACTACGCAATCCGGAAAGCTTTCCAAGTA
TGGAGTAATGTTACCCCCTTGAAATTCAGCAAGATTAACACAGGCATGGCTGACATTTTG
GTGGTTTTTGCCCGTGGAGCTCATGGAGACTTCCATGCTTTTGATGGCAAAGGTGGAATC
CTAGCCCATGCTTTTGGACCTGGATCTGGCATTGGAGGGGATGCACATTTCGATGAGGAC
GAATTCTGGACTACACATTCAGGAGGCACAAACTTGTTCCTCACTGCTGTTCACGAGATT
GGCCATTCCTTAGGTCTTGGCCATTCTAGTGATCCAAAGGCTGTAATGTTCCCCACCTAC
AAATATGTCGACATCAACACATTTCGCCTCTCTGCTGATGACATACGTGGCATTCAGTCC
CTGTATGGAGACCCAAAAGAGAACCAACGCTTGCCAAATCCTGACAATTCAGAACCAGCT
CTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGTGGGAAATAAGATCTTTTTC
TTCAAAGACAGGTTCTTCTGGCTGAAGGTTTCTGAGAGACCAAAGACCAGTGTTAATTTA
ATTTCTTCCTTATGGCCAACCTTGCCATCTGGCATTGAAGCTGCTTATGAAATTGAAGCC
AGAAATCAAGTTTTTCTTTTTAAAGATGACAAATACTGGTTAATTAGCAATTTAAGACCA
GAGCCAAATTATCCCAAGAGCATACATTCTTTTGGTTTTCCTAACTTTGTGAAAAAAATT
GATGCAGCTGTTTTTAACCCACGTTTTTATAGGACCTACTTCTTTGTAGATAACCAGTAT
TGGAGGTATGATGAAAGGAGACAGATGATGGACCCTGGTTATCCCAAACTGATTACCAAG
AACTTCCAAGGAATCGGGCCTAAAATTGATGCAGTCTTCTATTCTAAAAACAAATACTAC
TATTTCTTCCAAGGATCTAACCAATTTGAATATGACTTCCTACTCCAACGTATCACCAAA
ACACTGAAAAGCAATAGCTGGTTTGGTTGTTAG

# Drug_Target_2_General_Function:
Involved in protease activity

# Drug_Target_2_General_References:
11575928	Lang R, Kocourek A, Braun M, Tschesche H, Huber R, Bode W, Maskos K: Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J Mol Biol. 2001 Sep 28;312(4):731-42.
11575929	Nar H, Werle K, Bauer MM, Dollinger H, Jung B: Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J Mol Biol. 2001 Sep 28;312(4):743-51.
8226919	Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993 Nov 15;268(32):23824-9.
9115292	Gronski TJ Jr, Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD: Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 1997 May 2;272(18):12189-94.

# Drug_Target_2_HGNC_ID:
HGNC:7158

# Drug_Target_2_HPRD_ID:
03027

# Drug_Target_2_ID:
2203

# Drug_Target_2_Locus:
11q22.3

# Drug_Target_2_Molecular_Weight:
54002

# Drug_Target_2_Name:
Macrophage metalloelastase

# Drug_Target_2_Number_of_Residues:
470

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_2_Protein_Sequence:
>Macrophage metalloelastase precursor
MKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYSGNLM
KEKIQEMQHFLGLKVTGQLDTSTLEMMHAPRCGVPDVHHFREMPGGPVWRKHYITYRINN
YTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDFHAFDGKGGI
LAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTY
KYVDINTFRLSADDIRGIQSLYGDPKENQRLPNPDNSEPALCDPNLSFDAVTTVGNKIFF
FKDRFFWLKVSERPKTSVNLISSLWPTLPSGIEAAYEIEARNQVFLFKDDKYWLISNLRP
EPNYPKSIHSFGFPNFVKKIDAAVFNPRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITK
NFQGIGPKIDAVFYSKNKYYYFFQGSNQFEYDFLLQRITKTLKSNSWFGC

# Drug_Target_2_Reaction:
Hydrolysis of soluble and insoluble elastin [1]. Specific cleavages are also produced at -Ala14!Leu- and -Tyr16!Leu- in the B chain of insulin [2]

# Drug_Target_2_Signals:
1-16

# Drug_Target_2_Specific_Function:
May be involved in tissue injury and remodeling. Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3

# Drug_Target_2_SwissProt_ID:
P39900

# Drug_Target_2_SwissProt_Name:
MMP12_HUMAN

# Drug_Target_2_Synonyms:
EC 3.4.24.65
HME
ME
MMP-12
Macrophage elastase
Macrophage metalloelastase precursor
Matrix metalloproteinase-12

# Drug_Target_2_Theoretical_pI:
8.98

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
MMP3

# Drug_Target_3_GenBank_ID_Gene:
X05232

# Drug_Target_3_GenBank_ID_Protein:
36633

# Drug_Target_3_GeneCard_ID:
MMP3

# Drug_Target_3_Gene_Name:
MMP3

# Drug_Target_3_Gene_Sequence:
>1434 bp
ATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTG
GATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAAC
TACTACGACCTCAAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTT
GTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGAC
TCCGACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGATGTTGGTCACTTC
AGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAAT
TATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTC
TGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATG
ATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTT
TTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGAT
GAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATT
GGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTAT
CACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAG
TCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTC
CCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGC
ACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGG
AAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTG
GATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTC
TGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGT
TTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACA
TATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCA
GGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTT
TTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCA
AATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTTGA

# Drug_Target_3_General_Function:
Involved in protease activity

# Drug_Target_3_General_References:
10422833	Pavlovsky AG, Williams MG, Ye QZ, Ortwine DF, Purchase CF 2nd, White AD, Dhanaraj V, Roth BD, Johnson LL, Hupe D, Humblet C, Blundell TL: X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci. 1999 Jul;8(7):1455-62.
10543949	Chen L, Rydel TJ, Gu F, Dunaway CM, Pikul S, Dunham KM, Barnett BL: Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes. J Mol Biol. 1999 Oct 29;293(3):545-57.
2383557	Nagase H, Enghild JJ, Suzuki K, Salvesen G: Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 1990 Jun 19;29(24):5783-9.
3030290	Whitham SE, Murphy G, Angel P, Rahmsdorf HJ, Smith BJ, Lyons A, Harris TJ, Reynolds JJ, Herrlich P, Docherty AJ: Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J. 1986 Dec 15;240(3):913-6.
3360803	Saus J, Quinones S, Otani Y, Nagase H, Harris ED Jr, Kurkinen M: The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem. 1988 May 15;263(14):6742-5.
3477804	Wilhelm SM, Collier IE, Kronberger A, Eisen AZ, Marmer BL, Grant GA, Bauer EA, Goldberg GI: Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6725-9.
7656014	Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL, Hermes JD, Esser CK, Hagmann WK, Springer JP, et al.: The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol. 1994 Feb;1(2):111-8.
8535233	Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, Hermes JD, et al.: Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 1995 Oct;4(10):1966-76.
8740360	Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB Jr, Rubin JR, Pavlovsky A, Humblet C, Blundell TL: X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure. 1996 Apr 15;4(4):375-86.
9083493	Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK, et al.: Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. J Med Chem. 1997 Mar 14;40(6):1026-40.
9288970	Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W: Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997 Sep 4;389(6646):77-81.
9760240	Li YC, Zhang X, Melton R, Ganu V, Gonnella NC: Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry. 1998 Oct 6;37(40):14048-56.
9792098	Finzel BC, Baldwin ET, Bryant GL Jr, Hess GF, Wilks JW, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ, Schostarez HJ, Mitchell MA: Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci. 1998 Oct;7(10):2118-26.
9827994	Stockman BJ, Waldon DJ, Gates JA, Scahill TA, Kloosterman DA, Mizsak SA, Jacobsen EJ, Belonga KL, Mitchell MA, Mao B, Petke JD, Goodman L, Powers EA, Ledbetter SR, Kaytes PS, Vogeli G, Marshall VP, Petzold GL, Poorman RA: Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci. 1998 Nov;7(11):2281-6.

# Drug_Target_3_HGNC_ID:
HGNC:7173

# Drug_Target_3_HPRD_ID:
01703

# Drug_Target_3_ID:
1926

# Drug_Target_3_Locus:
11q22.3

# Drug_Target_3_Molecular_Weight:
53978

# Drug_Target_3_Name:
Stromelysin-1

# Drug_Target_3_Number_of_Residues:
477

# Drug_Target_3_PDB_ID:
1SLM

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_3_Protein_Sequence:
>Stromelysin-1 precursor
MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPV
VKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVN
YTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNV
LAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLY
HSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVS
TLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQF
WAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEP
GFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC

# Drug_Target_3_Reaction:
Preferential cleavage where P1', P2' and P3' are hydrophobic residues

# Drug_Target_3_Signals:
1-17

# Drug_Target_3_Specific_Function:
Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase

# Drug_Target_3_SwissProt_ID:
P08254

# Drug_Target_3_SwissProt_Name:
MMP3_HUMAN

# Drug_Target_3_Synonyms:
EC 3.4.24.17
MMP-3
Matrix metalloproteinase-3
SL-1
Stromelysin-1 precursor
Transin-1

# Drug_Target_3_Theoretical_pI:
6.07

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Secreted, extracellular space, extracellular matrix (By similarity)

# Drug_Target_4_Chromosome_Location:
1

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Y12779

# Drug_Target_4_GenBank_ID_Protein:
3005946

# Drug_Target_4_GeneCard_ID:
MMP20

# Drug_Target_4_Gene_Name:
MMP20

# Drug_Target_4_Gene_Sequence:
>1452 bp
ATGAAGGTGCTCCCTGCATCTGGCCTTGCTGTCTTCCTCATCATGGCTTTGAAGTTTTCC
ACTGCAGCCCCCTCCCTAGTTGCAGCCTCCCCCAGGACCTGGAGGAACAACTACCGCCTC
GCACAGGCGTATCTTGACAAATATTACACAAATAAAGAAGGACACCAGATTGGTGAGATG
GTTGCAAGAGGAAGCAATTCCATGATAAGGAAGATTAAGGAGCTACAAGCGTTCTTTGGC
CTCCAAGTCACCGGGAAGTTAGACCAGACCACAATGAACGTGATCAAGAAGCCTCGCTGT
GGAGTTCCTGATGTGGCCAATTATCGCCTCTTCCCTGGTGAACCCAAATGGAAAAAAAAT
ACTTTGACATACAGAATATCTAAATACACACCTTCCATGAGTTCTGTCGAGGTGGACAAA
GCAGTGGAGATGGCCTTGCAGGCCTGGAGTAGCGCCGTCCCTCTGAGCTTTGTCAGAATA
AACTCAGGAGAAGCGGATATTATGATATCTTTTGAAAATGGAGATCACGGGGATTCCTAT
CCATTCGATGGGCCTCGGGGGACTCTAGCCCATGCATTTGCTCCTGGAGAAGGCCTGGGA
GGAGATACACATTTCGACAATCCTGAGAAGTGGACTATGGGAACGAATGGTTTTAATTTG
TTTACCGTTGCTGCTCATGAATTTGGCCATGCCCTGGGCCTGGCCCATTCCACAGACCCA
TCAGCACTGATGTACCCAACTTATAAGTACAAGAATCCCTATGGATTCCACCTCCCCAAA
GATGATGTGAAAGGGATCCAGGCATTATACGGACCTCGGAAAGTATTCCTGGGGAAGCCC
ACTCTGCCCCATGCCCCCCATCACAAGCCATCCATCCCTGACCTCTGTGACTCCAGCTCA
TCCTTTGACGCTGTGACAATGCTGGGGAAGGAGCTCCTGCTCTTCAAGGACCGGATTTTC
TGGAGACGGCAGGTTCACTTGCGGACAGGAATTCGGCCCAGCACTATTACCAGCTCCTTC
CCCCAGCTCATGTCCAATGTGGATGCAGCTTACGAAGTGGCTGAGAGGGGCACTGCTTAC
TTCTTCAAAGGTCCCCACTACTGGATAACAAGAGGATTCCAAATGCAAGGTCCTCCTCGG
ACTATTTATGACTTTGGATTTCCAAGGCACGTGCAGCAAATAGATGCTGCTGTCTACCTC
AGGGAGCCACAGAAGACCCTTTTCTTTGTGGGAGATGAATACTACAGCTACGACGAAAGG
AAAAGGAAAATGGAAAAAGACTATCCAAAGAATACTGAAGAAGAATTTTCAGGAGTAAAT
GGCCAAATCGATGCTGCTGTAGAATTAAATGGCTACATTTACTTCTTTTCAGGACCAAAA
ACATACAAGTATGACACAGAGAAGGAAGATGTGGTTAGTGTGGTGAAATCTAGTTCCTGG
ATTGGTTGCTAA

# Drug_Target_4_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_4_General_References:
10922468	Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendas AM, Llano E, Perris R, Di Cesare PE, Murphy G, Knauper V: Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 2000 Jul 28;478(1-2):52-6.
15744043	Kim JW, Simmer JP, Hart TC, Hart PS, Ramaswami MD, Bartlett JD, Hu JC: MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet. 2005 Mar;42(3):271-5.
9398237	Llano E, Pendas AM, Knauper V, Sorsa T, Salo T, Salido E, Murphy G, Simmer JP, Bartlett JD, Lopez-Otin C: Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry. 1997 Dec 9;36(49):15101-8.

# Drug_Target_4_HGNC_ID:
GNC:7167

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6195

# Drug_Target_4_Locus:
11q22.3

# Drug_Target_4_Molecular_Weight:
54359.4

# Drug_Target_4_Name:
Matrix metalloproteinase-20

# Drug_Target_4_Number_of_Residues:
483

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_4_Protein_Sequence:
>Matrix metalloproteinase-20
MKVLPASGLAVFLIMALTFSTAAPSLVAASPRTWRNNYRLAQAYLDKYYTNKEGHQIGEM
VARGSNSMIRKIKELQAFFGLQVTGKLDQTTMNVIKKPRCGVPDVANYRLFPGEPKWKKN
TLTYRISKYTPSMSSVEVDKAVEMALQAWSSAVPLSFVRINSGEADIMISFENGDHGDSY
PFDGPRGTLAHAFAPGEGLGGDTHFDNAEKWTMGTNGFNLFTVAAHEFGHALGLAHSTDP
SALMYPTYKYKNPYGFHLPKDDVKGIQALYGPRKVFLGKPTLPHAPHHKPSIPDLCDSSS
SFDAVTMLGKELLLFKDRIFWRRQVHLRTGIRPSTITSSFPQLMSNVDAAYEVAERGTAY
FFKGPHYWITRGFQMQGPPRTIYDFGFPRHVQQIDAAVYLREPQKTLFFVGDEYYSYDER
KRKMEKDYPKNTEEEFSGVNGQIDAAVELNGYIYFFSGPKTYKYDTEKEDVVSVVKSSSW
IGC

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-22

# Drug_Target_4_Specific_Function:
Degrades amelogenin, the major protein component of the enamel matrix and two of the macromolecules characterizing the cartilage extracellular matrix:aggrecan and the cartilage oligomeric matrix protein (COMP). May play a central role in tooth enamel formation

# Drug_Target_4_SwissProt_ID:
O60882

# Drug_Target_4_SwissProt_Name:
MMP20_HUMAN

# Drug_Target_4_Synonyms:
Enamel metalloproteinase
Enamelysin
MMP-20

# Drug_Target_4_Theoretical_pI:
9.08

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB08271
